TABLE 5.
Efficacy of V-r in reducing E. coli UTI89 burden in 24-h thigh muscle infection model in neutropenic CD-1 mice
| Group, total dose over 24 h (mg/kg) | Log10 (group geometric mean ± SD CFU/g) | Log10 change from vehicle (CFU/g) | P value (versus vehicle) |
|---|---|---|---|
| Pretreatment | 4.76 ± 0.18 | −4.95 | 0.0248 |
| Vehicle | 9.71 ± 0.17 | 0 | 0 |
| V-r, 200 | 5.60 ± 2.28 | −4.11 | 0.0217 |
| V-r, 400 | 3.27 ± 1.88 | −6.43 | <0.0001 |
| V-r, 700 | 2.58 ± 0.25 | −7.13 | <0.0001 |
| V-r, 1,050 | 2.08 ± 0.89 | −7.63 | <0.0001 |
| V-r, 1,400 | 2.68 ± 1.38 | −7.03 | <0.0001 |
| Vancomycin, 1,272 | 8.48 ± 1.31 | −1.23 | Not significant |
| Ciprofloxacin, 20 | 3.32 ± 0.14 | −6.39 | <0.0007 |